Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ECOZA vs LOTRIMIN AF
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Imidazole antifungal inhibiting ergosterol synthesis via CYP51, disrupting fungal cell membrane permeability.
Inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Topical treatment of tinea pedis, tinea cruris, tinea corporis, tinea versicolor, and cutaneous candidiasis
Tinea pedis,Tinea cruris,Tinea corporis,Pityriasis versicolor,Cutaneous candidiasis
For vulvovaginal candidiasis: One vaginal suppository (150 mg) inserted intravaginally at bedtime for 3 consecutive days. For cutaneous candidiasis: Apply cream (1%) to affected area twice daily for 2-4 weeks.
Topical: Apply twice daily (morning and evening) to affected area for 2-4 weeks. Intravaginal: One 200 mg suppository vaginally at bedtime for 3 days, or one 500 mg vaginal tablet as a single dose.
Terminal elimination half-life is approximately 24–30 hours, allowing for once-daily dosing.
Terminal elimination half-life of absorbed clotrimazole is approximately 3.5–4 hours, but this is clinically irrelevant due to negligible systemic absorption after topical application.
Not extensively metabolized; minimal systemic absorption after topical application.
Minimal systemic absorption; primarily local metabolism.
Primarily hepatic metabolism; <1% excreted renally as unchanged drug. Fecal excretion accounts for ~57% of metabolites.
Less than 1% of topical clotrimazole is absorbed; absorbed drug is metabolized in the liver to inactive metabolites and excreted primarily in feces (approximately 69%) and urine (approximately 21%) via biliary and renal routes.
Approximately 89–93% bound to plasma proteins, primarily albumin.
Approximately 90–95% bound to plasma proteins, primarily albumin.
Apparent volume of distribution is approximately 2–3 L/kg, indicating extensive tissue penetration.
Vd is approximately 2.5 L/kg after intravenous administration (data for systemic formulation); after topical application, systemic absorption is negligible (<1%), so Vd is not clinically meaningful.
Oral bioavailability is approximately 37% (range 20–70%) due to first-pass metabolism; topical bioavailability is negligible systemically.
Topical: Systemic bioavailability is <1% after application to intact skin; vaginal tablet: approximately 3–10% absorbed systemically.
No dosage adjustment required for renal impairment. Systemic absorption is minimal after topical or intravaginal use.
No dosage adjustment required for renal impairment.
No dosage adjustment required for hepatic impairment due to minimal systemic absorption.
No dosage adjustment required for hepatic impairment.
Safety and efficacy in pediatric patients have not been established for vaginal use. For cutaneous candidiasis: Apply cream (1%) to affected area twice daily; duration based on clinical response. Weight-based dosing not applicable.
Children ≥2 years: Same as adult dosing for topical application. Children <2 years: Not recommended without physician consultation.
No specific dose adjustment required; use same dosing as for younger adults. Monitor for local irritation or adverse effects.
No specific dose adjustment; use same adult dosing with consideration of renal/hepatic function and potential drug interactions.
None
None
For external use only; avoid contact with eyes; discontinue if hypersensitivity occurs.
For external use only,Avoid contact with eyes,Discontinue if irritation occurs,Not for vaginal or oral use
Known hypersensitivity to imidazole antifungals or any component of the formulation
Hypersensitivity to clotrimazole or any component
No clinically significant food interactions for topical econazole nitrate. Avoid alcohol if using oral antifungal concurrently (not applicable here).
No clinically significant food interactions for topical clotrimazole.
ECOZA (econazole nitrate) is pregnancy category C. First trimester: no adequate studies; avoid unless benefit outweighs risk. Second/third trimester: minimal absorption after topical application, unlikely to cause fetal harm; however, prolonged use near term is not recommended due to theoretical risk of premature ductus arteriosus closure if systemic absorption occurs.
Clotrimazole (Lotrimin AF) is category B. No evidence of teratogenicity in animal studies. Limited human data from topical use in first trimester show no increased risk of major malformations. Systemic absorption from topical application is minimal (<0.5%), making fetal exposure negligible. No known fetal risks from topical use in any trimester.
Not known if econazole is excreted in human milk. M/P ratio not available. Due to low systemic absorption after topical use, risk to nursing infant is considered low. Caution if applied to breast area; avoid infant ingestion.
Topical clotrimazole is considered compatible with breastfeeding. Systemic absorption is minimal, and any excreted amounts in breast milk are negligible. M/P ratio is not available due to minimal absorption. Avoid application to breast area to prevent infant oral contact.
No dose adjustment needed. Pharmacokinetic changes in pregnancy (e.g., increased skin blood flow, hydration) may slightly alter absorption but clinical significance is minimal. Use standard topical dosing as prescribed.
No dose adjustment required for topical clotrimazole during pregnancy. Pharmacokinetics are not significantly altered as systemic absorption is minimal. Use standard dosing for indication (e.g., 1% cream twice daily for 2-4 weeks for dermatophytosis).
Ecoza (econazole nitrate) is a topical azole antifungal. Avoid use on open wounds or broken skin. Apply once daily for 4 weeks for tinea pedis; 2 weeks for tinea cruris/corporis. Do not use occlusive dressings. Monitor for local irritation, burning, or allergic contact dermatitis.
Lotrimin AF (clotrimazole) is a topical antifungal used for dermatophyte and yeast infections. For tinea pedis, apply twice daily for 4 weeks; shorter courses may lead to recurrence. Do not use in or near eyes. Avoid occlusive dressings unless directed.
Apply a thin layer to cleaned, dry affected area and surrounding skin once daily or as directed.,Wash hands before and after application unless treating hands.,Use for the full prescribed duration even if symptoms improve to prevent recurrence.,Avoid contact with eyes, mouth, or mucous membranes. If contact occurs, rinse with water.,Do not cover the treated area with bandages or wrappings unless instructed by your doctor.,Inform your doctor if symptoms persist after 2 weeks or worsen, or if severe irritation occurs.,Store at room temperature away from moisture and heat.
Apply a thin layer to affected skin twice daily, morning and evening.,Wash hands before and after application unless treating hands.,Continue use for the full prescribed duration even if symptoms improve.,Avoid contact with eyes, mouth, or open wounds.,Do not cover treated area with bandages or plastic unless instructed.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ECOZA vs LOTRIMIN AF, answered by our medical review team.
ECOZA is a Topical Antifungal that works by Imidazole antifungal inhibiting ergosterol synthesis via CYP51, disrupting fungal cell membrane permeability.. LOTRIMIN AF is a Topical Antifungal that works by Inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ECOZA and LOTRIMIN AF depend on the specific clinical indication. These are both Topical Antifungal agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ECOZA is: For vulvovaginal candidiasis: One vaginal suppository (150 mg) inserted intravaginally at bedtime for 3 consecutive days. For cutaneous candidiasis: Apply cream (1%) to affected area twice daily for 2-4 weeks.. The standard adult dose of LOTRIMIN AF is: Topical: Apply twice daily (morning and evening) to affected area for 2-4 weeks. Intravaginal: One 200 mg suppository vaginally at bedtime for 3 days, or one 500 mg vaginal tablet as a single dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ECOZA and LOTRIMIN AF in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ECOZA is classified as Category C. ECOZA (econazole nitrate) is pregnancy category C. First trimester: no adequate studies; avoid unless benefit outweighs risk. Second/third trimester: minimal absorption after topic. LOTRIMIN AF is classified as Category C. Clotrimazole (Lotrimin AF) is category B. No evidence of teratogenicity in animal studies. Limited human data from topical use in first trimester show no increased risk of major ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.